PROTALIX BIOTHERAPEUTICS INC

Protalix Biotherapeutics stalls at $2.55, 8% down, amid weak liquidity and a sluggish biotech sector. Find out why the promise of plant‑cell tech hasn’t translated into market momentum.

Protalix Biotherapeutics trading update: USD 2.57 per share, 2.65% decline, 24‑hour change –9.51%, market cap $211M. Get the latest price, metrics & market comparison.

Protalix Biotherapeutics (PLX) gains 3.12% as its price tops the 200‑day moving average, signaling potential momentum amid sector volatility.

Protalix Biotherapeutics shares dip 2.3% to $2.64 amid low liquidity, yet still trade at a discount to 52‑week highs, offering a potential entry for value‑focused biotech investors.